Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
ClinicalTrials.gov: NCT04881760 (Phase 2, Obesity), NCT04867785 (Phase 2, T2D) Questions to ask your doctor Given my health history, is a GLP-1 medication appropriate for me at all
Its anti-fibrotic action makes it particularly well-studied in models of chronic injury, cardiac fibrosis, and musculoskeletal lesions (Malinda et al., J Invest Dermatol 1999)
10.1016/S2468-1253(21)00296-X Summary Keywords fatty liver, non-alcoholic fatty liver disease, MAFLD, Vietnam, metabolic syndrome, epidemiology, public health, liver cirrhosis Citation Vo TD and Lam HT (2025) MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action
Unauthorized distribution, possession, or use is strictly prohibited by law and may constitute a violation of regulatory requirements
For example, data presented at the European Congress on Obesity in May 2024 showed that patients who tapered their semaglutide dosage over an average of 9 weeks maintained stable body weight for at least 26 weeks
